responses of airway smooth muscle (ASM) determine airway resistance in health and disease. Caveolae microdomains in the plasma membrane are marked by caveolin proteins and are abundant in contractile smooth muscle in association with nanospaces involved in Ca 2ϩ homeostasis. Caveolin-1 can modulate localization and activity of signaling proteins, including trimeric G proteins, via a scaffolding domain. We investigated the role of caveolae in contraction and intracellular Ca 2ϩ ([Ca 2ϩ ]i) mobilization of ASM induced by the physiological muscarinic receptor agonist, acetylcholine (ACh). Human and canine ASM tissues and cells predominantly express caveolin-1. Muscarinic M3 receptors (M3R) and G␣q/11 cofractionate with caveolin-1-rich membranes of ASM tissue. Caveolae disruption with ␤-cyclodextrin in canine tracheal strips reduced sensitivity but not maximum isometric force induced by ACh. In fura-2-loaded canine and human ASM cells, exposure to methyl-␤-cyclodextrin (m␤CD) reduced sensitivity but not maximum [Ca 2ϩ ]i induced by ACh. In contrast, both parameters were reduced for the partial muscarinic agonist, pilocarpine. Fluorescence microscopy revealed that m␤CD disrupted the colocalization of caveolae-1 and M 3R, but [N-methyl-3 H]scopolamine receptor-binding assay revealed no effect on muscarinic receptor availability or affinity. To dissect the role of caveolin-1 in ACh-induced [Ca 2ϩ ]i flux, we disrupted its binding to signaling proteins using either a cell-permeable caveolin-1 scaffolding domain peptide mimetic or by small interfering RNA knockdown. Similar to the effects of m␤CD, direct targeting of caveolin-1 reduced sensitivity to ACh, but maximum [Ca 2ϩ ]i mobilization was unaffected. These results indicate caveolae and caveolin-1 facilitate [Ca 2ϩ ]i mobilization leading to ASM contraction induced by submaximal concentrations of ACh.
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caveolin; G protein-coupled receptor; asthma; histamine; G␣ q CHOLESTEROL-AND SPHINGOLIPID-enriched plasma membrane invaginations called caveolae are abundant in mature smooth muscle cells (7) . As sites where many receptors, ion channels, and signaling effectors are sequestered, caveolae can play a key role in modulating pathways associated with cell proliferation, migration, and contraction (7, 26) . Caveolae are uniquely characterized by the presence of cholesterol-binding proteins, the caveolins, that form an oligomeric network along the inner leaflet of the plasma membrane (1, 10) . Caveolin-1, which is sufficient to drive new caveolae formation when overexpressed in a number of cell types (11, 44) , is the primary caveolin protein expressed by smooth muscle (21, 48) . Caveolin-1 expression is markedly increased in smooth muscle cells as they attain a fully contractile phenotype, an observation we (21) recently confirmed for cultured human airway myocytes. Caveolin-2 is also expressed in smooth muscle tissue, and some reports indicate caveolin-3 is present in vascular smooth muscle (48) . Caveolin-1 contains an important functional domain near its NH 2 terminus, the so-called caveolin scaffolding domain (CSD), which interacts with and regulates signaling proteins, including several that are central to G protein-coupled receptor (GPCR)-mediated smooth muscle contraction (7, 8, 34, 35) .
Several studies support a possible role for caveolae and caveolins in GPCR-mediated smooth muscle contraction. In vascular and gastrointestinal smooth muscle, caveolae harbor a number of GPCR-regulated signaling proteins, including ␣-subunits of trimeric G proteins, PLC, the monomeric G protein RhoA and its downstream effector Rho kinase, and Ca 2ϩ -sensitive PKC isoforms (4, 6, 38, 48, 50, 52, 55) . Somara et al. (50) recently showed that ectopic overexpression of caveolin-1 in aged rabbit colonic smooth muscle restored muscarinic receptor-mediated contraction, suggesting a facilitator role. Consistent with this observation, disruption of caveolae using cholesterol-depleting agents leads to reduced contraction of vascular smooth muscle in response to endothelin-1 or serotonin (2, 12) . Using a cell-permeable CSD peptide that blocks caveolin-1 interactions with signaling proteins but leaves caveolae intact, Je et al. (28) reported a significant suppression in contractile responses of ferret aortic smooth muscle to ␣-adrenergic agonist. Notably, caveolin-1 has tissueand receptor-specific effects on smooth muscle contraction; using tissue from caveolin-1 knockout mice, Shakirova et al. (48) observed that ileum longitudinal muscle had reduced contraction to endothelin-1 with no change in response to 5-HT or carbachol, whereas femoral arterial muscle contraction was increased in response to ␣ 1 -adrenergic receptor stimulation. Collectively, these observations point to agonist-and tissuespecific role for caveolae and caveolin-1 in modulating receptor-mediated smooth muscle contraction.
In contractile smooth muscle cells, caveolae distribution is highly ordered, being concentrated in longitudinal plasma membrane arrays that lie in close proximity to intracellular sarcoplasmic reticulum and mitochondria, thereby forming nanospaces for Ca 2ϩ homeostasis (17, 18, 40) . Ultrastructural studies confirm this spatial orientation in airway smooth muscle (ASM; Ref. 31) , and biochemical fractionation of caveolae from canine trachealis has revealed that caveolae are enriched in number of Ca 2ϩ -handling proteins, including L-type Ca 2ϩ channels, the Ca 2ϩ -binding proteins calsequestrin and calreticulin, and the plasma membrane Ca 2ϩ pump (9) . In a recent electrophysiological study using isolated rat cerebral resistance arterial myocytes, Kamishima et al. (29) showed that caveolin-1 inhibition with CSD peptide or selective antibodies markedly slowed Ca 2ϩ removal rate after stimulation to physiologically relevant cytoplasmic Ca 2ϩ concentrations. Collectively, these studies suggest that effects of caveolae disruption or caveolin-1 depletion on GPCR-mediated smooth muscle contraction may be underpinned, in part, by changes in intracellular Ca 2ϩ ([Ca 2ϩ ] i ) flux. Despite the association of Ca 2ϩ -handling proteins with caveolae in ASM and compelling evidence from other smooth muscle tissues that GPCR-mediated contraction is modulated by caveolae and caveolin-1, the role of caveolae in functional excitation-contraction coupling in ASM has not yet been reported. Therefore, in the current study, we tested the hypothesis that caveolin and caveolin-1 modulate [Ca 2ϩ ] i mobilization and associated contractile responses induced by physiologically relevant agonists in human and canine ASM. We used biochemical fractionation of cells and tissues to assess subcellular distribution of muscarinic M 3 receptors (M 3 R) and G␣ q/11 subunits that transduce ligand-induced cell responses. We also used cholesterol depletion, small interfering RNA (siRNA) knockdown of caveolin-1, and treatment with cell-permeable caveolin-1 CSD peptide to determine the functional role of caveolae and caveolin-1 in muscarinic receptor-mediated Ca 2ϩ flux in primary cultured ASM and contraction of intact tracheal smooth muscle (TSM). Our results are significant, as they describe for the first time a novel role for caveolae and caveolin-1 in ASM contractile responses, and thus they are of relevance to understanding mechanisms that control airway resistance in health and disease.
MATERIALS AND METHODS
Cell culture. Canine and human ASM cells were used for cell culture studies. Primary cultured canine airway myocytes were established from dissociated canine trachealis as we (25, 37) have described previously. Human bronchial smooth muscle cell lines immortalized by stable expression of human telomerase reverse transcriptase (hTERT) were prepared as described previously (21) . The primary cultured human bronchial smooth muscle cells used to generate hTERT ASM cells were prepared from macroscopically healthy segments of 2nd-to-4th generation main bronchus obtained after lung resection surgery from patients with a diagnosis of adenocarcinoma. Cells were grown to confluence using DMEM supplemented with 10% fetal bovine serum, 50 U/ml streptomycin, and 50 g/ml penicillin. Cultures were maintained in a humidified incubator at 37°C-5% CO 2, and media was changed every 2 days. For the induction of contractile phenotype myocytes, confluent cultures of canine (passage 0 or 1) or human ASM cell (passages 9-15) were serum-deprived for 4 -10 days using Ham's F-12 medium supplemented with 5 g/ml insulin, 5 g/ml transferrin, and 5 ng/ml selenium (ITS) as described previously (21, 25) .
Isolation of caveolae-enriched membrane fractions. Cells grown on uncoated 150-mm dishes were washed with ice-cold PBS and lysed in 500 mM sodium carbonate (pH 11.0) supplemented with 1 mM Na 3VO4, 10 g/ml aprotinin, 10 g/ml leupeptin, 7 g/ml pepstatin A, and 1 mM PMSF. After homogenization by sonification, 2 ml of homogenate was mixed with an equal volume of a solution containing 150 mM NaCl, 25 mM MES (pH 6.5), and 80% (wt/vol) sucrose and placed in the bottom of a centrifuge tube. A stepwise sucrose density gradient (45%, 30%, 20%, and 5%) was then carefully layered on top of the homogenate. Thereafter, the samples were centrifuged at 210,000 g for 18 h, and then 1-ml fractions were collected from the top of the gradient. Samples were stored at Ϫ80°C until further use.
Preparation of total protein lysates from ASM tissue. Intact ASM tissue was isolated from human bronchial specimens or canine trachealis by microdissection at 4°C. Thereafter, tissues were homogenized by sonification in ice-cold in RIPA buffer and subjected to centrifugation (760 g, 5 min), and the supernatant was stored at Ϫ80°C for subsequent protein assay and immunoblot analyses.
Western blot analysis. Protein content in supernatant samples was determined using the Bio-Rad protein assay with BSA as a reference (Bio-Rad, Hercules, CA). Equal amounts of protein from sucrose density-isolated fractions or total protein lysates were subjected to electrophoresis, transferred to nitrocellulose membranes, and analyzed for the proteins of interest using specific primary and horseradish peroxidase (HRP)-conjugated secondary antibodies as we (25) have previously described. Bands were subsequently visualized on film using ECL reagents.
Transmission electron microscopy. The ultrastructure of intact canine trachealis was assessed. Specimens consisting of two cartilage rings with intact trachealis were prepared from the cervical segments using a sharp scalpel. Specimens were incubated at 37°C in oxygenated Krebs-Henseleit solution (KH; 117.5 mM NaCl, 5.6 mM KCl, 1.18 mM MgSO4, 2.5 mM CaCl2, 1.28 mM NaH2PO4, 25 mM NaHCO3, and 5.55 mM D-glucose, gassed with 5% CO2 and 95% O2, 37°C, pH 7.4) for 1 h in the presence or absence of ␤-cyclodextrin (␤-CD; 10 mM), which depletes cholesterol and thereby disrupts lipid rafts including caveolae. Specimens were washed once with fresh KH buffer and fixed in PBS (pH 7.4) containing 4% paraformaldehyde-1.25% glutaraldehyde at room temperature for 48 h. Thereafter, the smooth muscle layer was removed from each ring and subjected to postfixation with 1% osmium tetroxide and embedded in LX-112 acrylic medium. Ultrathin cross-sections of the muscle tissue were then prepared, mounted onto coated grids, and stained with 1% uranyl acetate and lead citrate. Cell ultrastructure was assessed with an electron microscope at an acceleration voltage of 60 -80 kV.
Contraction studies. Canine TSM was dissected free from the cartilage, the adventitia, and the submucosal layers. The muscle was then cut into strips ϳ2 mm wide and mounted for isometric recording in water-jacketed organ baths containing KH buffer and allowed to equilibrate at a passive resting force of ϳ1.2 g for 1 h. Buffer was then replaced with isosmotic KH containing 47 mM KCl. The active force generated by KCl exposure was measured three times with 15-min washouts between each stimulation. Muscle strips were then stimulated using a single concentration of acetylcholine (ACh) for each preparation. After ACh exposure, chambers were washed out, and the strips were incubated for 1 h in KH or in KH containing 10 mM ␤-CD to disrupt caveolae. Thereafter, muscle chambers were washed out repeatedly, and muscle strips were reexposed to the same concentration of ACh used for the initial stimulation. To ensure muscle strip viability, after the final ACh exposure, chambers were washed, and muscle strips were again stimulated with isosmotic KH containing 47 mM KCl. Any muscle strips that exhibited a change of more than 15% in active tension compared with that obtained with last KCl exposure before the ACh protocol were not included for data analysis.
Immunocytochemistry. ASM cells were plated onto precleared glass coverslips in six-well culture dishes. Cells were fixed for 15 min at 4°C in cytoskeletal buffer (10 mM MES, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl2, and 5 mM glucose, pH 6.1) containing 3% paraformaldehyde. Cells were then permeabilized by incubation for 5 min at 4°C in cytoskeletal buffer containing 3% paraformaldehyde and 0.3% Triton X-100. For immunofluorescence microscopy, fixed cells were first blocked for 2 h at room temperature in Cyto-TBS buffer (20 -sensitive ratiometric fluorescent dye fura-2 AM as we (37) have described previously. All measurements were carried out using myocytes grown on glass coverslips or chamber slides. Myocytes were washed briefly with HBSS/HEPES buffer containing 0.1% BSA and then incubated with 5 g/ml fura-2 AM (37°C, 1 h) in buffer supplemented with 0.01% pluronic acid. Cells were then washed three times and incubated in buffer for a further hour at room temperature to allow for fura-2 AM deesterification. Real-time changes in [Ca 2ϩ ]i were recorded using an Olympus LX-70 inverted epifluorescent microscope (ϫ20 objective) coupled to a Perkin-Elmer Ultra Pix FSI CCD camera controlled by UltraView imaging software. The system was further coupled to a Sutter Instruments Lambda 10-2 filter wheel and controller with repeated 200 -400 ms excitation at 340 and 380 nm; emission at 510 nm was recorded continually for up to 3 min after the addition of contractile agonists. Maximum change in [Ca 2ϩ ]i was calculated as the average baseline value subtracted from the peak [Ca 2ϩ ]i response to agonist. The ratio of emission at 510 nm excited by 340-and 380-nm light was converted to [Ca 2ϩ ]i values from a calibration curve generated using calcium standards and calculated by the method of Grynkiewicz (23) .
For studies examining the effects of cholesterol depletion on [Ca] i mobilization induced by contractile agonists, fura-2-loaded cells were incubated at room temperature for 1-1.5 h in buffer containing 10 mM ␤-CD or 5 mM methyl-␤-cyclodextrin (m␤CD). Controls cultures were incubated for the same time period in buffer only. For other experiments, before fura-2 loading, myocytes were incubated (1 h, 37°C) in HBSS/HEPES containing a cell-permeable rhodamine conjugated synthetic peptide (1 M) that included the human CSD amino acid sequence (residues 82-101) linked at the NH2 terminus with a 17-residue antennapedia (AT) protein transduction domain (RQIKIWFQNRRRMKWKK-DGIWKASFTTFTVTKYWFYR). For control experiments, cells were incubated with a rhodamine-conjugated synthetic peptide containing AT sequence linked to the NH 2-terminal residue of a scrambled CSD sequence (RQIKIWFQNRRRMKWKK-WGIDKAFFTTSTVTYKWFRY).
Muscarinic receptor-binding assay. Cells were grown on uncoated 150-mm dishes and subjected to 4 days of serum deprivation. Cultures were incubated in HEPES-HBSS for 1 h at 37°C with or without 5 mM m␤CD and then washed with ice-cold PBS and lysed on ice in 25 mM Tris, 2.5 mM CaCl 2 (pH 7.4), supplemented with 10 g/ml aprotinin, 10 g/ml leupeptin, 7 g/ml pepstatin A, and 1 mM PMSF. After 10 strokes in a Dounce homogenizer, the homogenate was centrifuged for 5 min (1,000 g). The supernatant was transferred to a new tube and centrifuged for 30 min (150,000 g). The pellet-containing membrane was resuspended by sonification and stored at Ϫ80°C until further use. Binding of [N-methyl- 3 (21) have previously described for studies in which total caveolin-1 protein abundance was reduced by 50 -60% 72 h after siRNA transfection. Cells were grown to 50 -70% confluence in chamber slides and transiently transfected in serum-free DMEM containing antibiotics with a 21-bp, double-stranded siRNA targeted against a sequence between residues 529 -589 of the caveolin-1 transcript (Qiagen, Mississauga, Ontario, Canada). Cells were transfected using 2.5 g/ml siRNA in combination with 6 l/g siRNA of RNAiFect transfection reagent (Qiagen). In all studies, control transfections were performed using a nonsilencing control 21-bp siRNA (Qiagen). Cells were washed with fresh DMEM 72 h after transfection and used immediately for experiments to assess changes in cytosolic Ca 2ϩ concentration in response to ACh. Materials. Cell culture media (DMEM and Ham's F-12), supplements (fetal bovine serum and ITS), and antibiotics (penicillin and streptomycin) were obtained from Invitrogen. Caveolin-1 primary antibody was from BD Biosciences (San Jose, CA). Muscarinic M 3R antibody was kindly provided by Dr. Jurgen Wess (National Institutes of Health, Bethesda, MD). G␣ q/11 primary antibody was from Santa Cruz Biotechnology (Santa Cruz, CA). FITC-and Cy5-conjugated secondary antibodies were from Jackson ImmunoResearch (West Grove, PA). ␤-Actin primary antibody, smooth muscle myosin heavy chain (smMHC) primary antibody, anti-rabbit, anti-mouse, and antigoat HRP-conjugated secondary antibodies, ␤-CD, and m␤CD were from Sigma-Aldrich (St. Louis, MO). Fura-2 AM dye and Hoechst 33342 nuclear stain were from Molecular Probes (Leiden, The Netherlands). ECL reagent was from Amersham (Oakville, Ontario, Canada). Rhodamine-conjugated synthetic CSD-and scrambled CSD-AT peptides were obtained from AnaSpec (San Jose, CA).
RESULTS
Caveolin expression and caveolae association of muscarinic M 3 R and G␣ q/11 . We first used immunoblotting to characterize the distribution of caveolins expressed in isolated ASM tissue from trachea or 2nd-to-3rd generation mainstem bronchi. Figure 1A shows that caveolin-1 (ϳ24 kDa) is the predominant isoform expressed in canine trachealis, human trachealis, and human bronchial smooth muscle. Although we were unable to detect a distinct band for caveolin-2 in canine trachealis lysates (even when the total protein loaded was increased 5-fold), caveolin-2 was abundant in human ASM lysates. In fact, three distinct bands for caveolin-2, which likely correspond to ␣-, ␤-, and ␥-isoforms of decreasing molecular weight, respectively, were visible in human ASM. Caveolin-3 was undetect-able in human ASM lysates; however, a pale band (ϳ21 kDa) for caveolin-3 was evident for canine trachealis in blots where the total protein load was increased by fivefold compared with that used to detect caveolin-1 in the same lysates.
We next used an established method for sucrose density gradient centrifugation of carbonate buffer cell lysates to investigate the subcellular distribution of muscarinic M 3 R and G␣ q/11 in isolated canine trachealis (Fig. 1B) and human bronchial smooth muscle tissue (Fig. 1C) . This technique separates caveolae-enriched membrane microdomains, as they are cholesterol-enriched and thus exhibit a light buoyant density (49) . As expected, caveolae were retrieved from 5-20% and 20 -30% sucrose gradient interfaces; this was confirmed using Western blotting that revealed a marked enrichment of caveolin-1 protein in fractions 4-7. Notably, the fractions in which M 3 R (fractions 3-7) and G␣ q/11 (fractions 2-8) were chiefly retrieved overlapped with caveolae-rich fractions for both canine and human ASM samples (Fig. 1) . Human bronchial smooth muscle lysates also revealed that a portion of M 3 R and G␣ q protein was present in caveolae-deficient samples, suggesting these proteins also exist in other cellular subcompartments.
Role of caveolae in ACh-induced ASM contraction. We next tested whether the association of muscarinic M 3 R and G␣ q/11 with caveolae was of functional significance. Therefore, we measured active isometric force generated by individual canine TSM strips in response to ACh exposure both before and after incubation with the cholesterol-depleting agent ␤-CD. When applied at concentrations of 5-10 mM, the hydrophobic core of ␤-CD and its analog m␤CD sequester cholesterol and thereby dramatically reduce membrane cholesterol content (30) . We first used transmission electron microscopy to confirm the ␤-CD protocol we used led to the disruption of caveolae (Fig. 2) . Although organized arrays of flask-shaped membrane invaginations characteristic of caveolae were readily apparent in control samples, we were unable to see any evidence of these structures after muscle strips had been incubated in ␤-CD.
We next tested whether the disruption of caveolae in canine TSM strips affected receptor-mediated contractile responses. We employed a protocol in which individual strips were first contracted with a single concentration of ACh (ACh1), and then, after repeated washes, strips were incubated for 1 h in KH buffer alone (control) or in KH buffer containing ␤-CD. Protein lysates were prepared in RIPA buffer and size-fractionated on 12% SDS acrylamide gels. Fresh canine tracheal smooth muscle (TSM), human TSM (obtained from healthy lung donors), or 2nd-to-3rd order human mainstem bronchial smooth muscle (BSM; obtained from lung resection subjects) were cleaned of nonmuscle tissues by fine dissection under a binocular microscope. For canine TSM blots, 5 g of total protein was loaded for Cav-1 detection, and 30 g of total protein was loaded for Cav-2 and Cav-3 lanes. For human TSM and BSM, 15 g of total protein was added in each lane. B: immunoblots showing distribution of Cav-1, M3R, and G␣q in cell fractions obtained from isolated canine TSM homogenized in carbonate buffer and subjected to sucrose-density gradient centrifugation as described in MATERIALS AND METHODS. After centrifugation, 1-ml fractions (designated by numbers above each lane in the gels shown) were collected starting from the top of each centrifuge tube. Equal volumes from each fraction were then subjected to Western blotting; 12% SDS-acrylamide gels were used for Cav-1 and G␣q, whereas 10% gels were used for M3R. Representative blots from 3 experiments are shown. C: immunoblots showing distribution of Cav-1, M3R, and G␣q in cell fractions obtained from isolated human BSM. Samples were obtained and assessed by immunoblots as described for canine BSM.
Thereafter, muscle baths were washed three times, and TSM strips were treated a second time with ACh (ACh2) of the same concentration used for the ACh1 step. This was repeated for multiple strips at ACh between 10 Ϫ10 -10 Ϫ4 M to construct full concentration-response curves. Figure 3A shows that ␤-CD treatment caused a significant rightward shift of the ACh2 response curve compared with the ACh1 curve (control) at low concentrations of agonist; this effect is reflected in the sensitivity of contractile responses to ACh (pEC 50 Fig. 3B shows contractile responses of individual TSM strips induced by 10 Ϫ7 and 10 Ϫ8 M ACh both before (ACh1) and after (ACh2) ␤-CD treatment. Active contractile force was unaffected in control strips, whereas at relatively low concentrations of ACh, each strip exhibited a variable decrease in contractile response after ␤-CD treatment. However, treatment with ␤-CD did not affect the time for the initiation of AChinduced contractile force nor did it affect the time to reach peak force. Notably, contractile responses elicited by ACh above 1 M were unaffected by caveolae disruption (Fig. 3A) , and caveolae disruption had no effect on maximum contractile force generating capacity, as active tension elicited by 47 mM KCl-supplemented isotonic KH buffer, which was used to normalize ACh-induced contractions, was unchanged after ␤-CD treatment (data not shown). Collectively, these observations indicate that caveolae modulate the sensitivity of ASM tissue for ACh, as indicated by a significant change in pEC 50 ] i induced by muscarinic receptor agonists. For this purpose, we first used primary cultured canine ASM cells subjected to prolonged serum deprivation, a protocol we (37) have previously shown induces a subpopulation of fully contractile myocytes that express abundant functional, cell surface muscarinic M 3 R. This cell subpopulation is characterized by an elongate morphology and accumulates contractile apparatus-associated proteins, including smMHC (27) . We used fluorescent immunocytochemistry to determine the effects of caveolae disruption on the distribution of caveolin-1 and M 3 R in contractile phenotype myocytes. In 7-to-10-day serum-deprived cultures, caveolin-1 and M 3 R are expressed abundantly in smMHC-enriched myocytes and arranged in longitudinal linear arrays, a pattern we (25, 26) have shown is characteristic for caveolae in contractile ASM cells in culture (Fig. 4, A and B) . To confirm that linear arrays of caveolin-1 and M 3 R are associated with caveolar membranes, we incubated serum-deprived ASM cultures with ␤-CD for 1 h before fixation and cell staining. Immunocytochemistry revealed that caveolae depletion caused a dramatic rearrangement in the typical longitudinal linear arrays of caveolin-1 and M 3 R in contractile myocytes (Fig. 4, C and D) .
We next measured the effects of cholesterol depletion on ACh-induced changes in [Ca 2ϩ ] i using ratiometric fluorescence microscopy of serum-deprived myocytes loaded with fura-2. Canine TSM cells were exposed to 1 M ACh (ACh1); thereafter, cultures were incubated (1 h) in buffer alone or in buffer containing ␤-CD, and then a second response to 1 M ACh (ACh2) was recorded in the cells that had exhibited a rise in [Ca 2ϩ ] i during the ACh1 step (Fig. 5A) . Although ACh1 induced a substantial, transient elevation in [Ca 2ϩ ] i ranging between 250 -550 nM, caveolae disruption with ␤-CD suppressed responses by ϳ50% in the same myocytes (Fig. 5B) . For these studies, we used m␤CD, as it is nearly twice as effective as ␤-CD in mediating cellular cholesterol release, and thus we were able to use a lesser concentration of m␤CD in our more rigorous experiments measuring concentration-response characteristics for different agonists. We (21, 53, 54) have shown previously that prolonged serum deprivation of human ASM cell cultures induces contractile phenotype maturation, and our current studies confirm that these cells also acquire responsiveness to muscarinic receptor stimulation (Fig. 6, A and B) . To assess the role of caveolae in muscarinic receptor-mediated responses, we compared the rise in [Ca 2ϩ ] i elicited by ACh between cultures that had been Fig. 4 . A-D: distribution of muscarinic M3R and Cav-1 in cultured, contractile phenotype canine tracheal myocytes. Primary canine TSM cells were grown to confluence on glass coverslips and subjected to 7-10 days of culture in serum-deficient conditions. Thereafter, myocytes were fixed, double-labeled for smooth muscle myosin heavy chain (smMHC) and Cav-1 or M3R, and imaged by fluorescent microscopy before (A and B) or after (C and D) incubation in media containing ␤-CD (10 mM, 1 h, 37°C). The left and middle panels in A-D are matched fields of similar magnification. The insets highlight areas of Cav-1 or M3R labeling that are shown as an enlarged image on the right of each set of images. Nuclei were counterstained with Hoechst 33342 (10 g/ml).
preequilibrated either in buffer alone or in buffer containing m␤CD (Fig. 6) . In a manner that mimicked the effects of cholesterol depletion on ACh-induced contraction of canine tracheal strips, caveolae disruption in cultured human ASM cells markedly reduced the magnitude of peak [Ca 2ϩ ] i induced by low concentrations of ACh (Ͻ1 M), but there were no effects at higher concentrations of ACh (Fig. 6A) . These effects are illustrated by a significant reduction in sensitivity to ACh in m␤CD-treated cultures (pEC 50 ϭ 6.42 Ϯ 0.04; 0.38 Ϯ 0.02 M) compared with control cultures (pEC 50 ϭ 6.83 Ϯ 0.06; 0.15 Ϯ 0.01 M; P Ͻ 0.05). Importantly, changes in active cytosolic Ca 2ϩ mobilization were not due to a shift in resting baseline [Ca 2ϩ ] i (control: 107.0 Ϯ 6.0 nM; m␤CD: 109.0 Ϯ 9.0 nM; n ϭ 100 cells in 3 cultures).
To more clearly elucidate the role of caveolae in facilitating M 3 R-mediated [Ca 2ϩ ] i release, we completed three additional analyses. First, as a significant muscarinic receptor signaling reserve exists in ASM stimulated with ACh (24, 36), we investigated whether this could account for the lack of effect of caveolae depletion on [Ca 2ϩ ] i responses elicited above the EC 50 for ACh. We performed experiments using the partial muscarinic agonist, pilocarpine, which requires binding to nearly all M 3 R to induce a maximum response. Notably, compared with control cultures, caveolae disruption reduced both sensitivity to pilocarpine (control: pEC 50 ] i release via G␣ q/11 -coupled H1 and B2 receptors, respectively. Unlike the effects on ACh, for histamine (Fig. 6C) (Fig. 6D) , as m␤CD had no significant effect on ligand sensitivity (control: pEC 50 (Figs. 5 and 6 ), and caveolin-1, which can serve as a scaffold and regulatory protein for a number of important intracellular signaling proteins (8) , is the principal caveolae marker protein in ASM cells (Fig. 1) , we next assessed the direct role of caveolin-1 in muscarinic receptor-mediated [Ca 2ϩ ] i release in cultured human ASM cells. We used a previously established selective siRNA strategy (21) to induce a 50 -60% decrease in caveolin-1 protein abundance in human ASM cell cultures 3 days after siRNA transfection (Fig. 7) . Figure 7B shows that, compared with cells transfected with nonsilencing control siRNA, myocytes transfected with caveolin-1 siRNA exhibited a marked suppression in peak [Ca . These data indicate that caveolin-1 knockdown impairs muscarinic receptor-mediated cytosolic Ca 2ϩ release in a pattern and magnitude that mimics the effects of cholesterol depletion with m␤CD (Fig. 6) . In additional analyses of the effects of caveolin-1 siRNA, we found loss of caveolin-1 significantly reduced the number of cells per field that exhibited an active increase in [Ca 2ϩ ] i in response to ACh, in particular at 0.01 M where almost 50% fewer cells were seen to mobilize cytosolic Ca 2ϩ above baseline values (Fig. 7C) . Collectively, these results indicate a central role exists for caveolin-1 in human ASM cells to facilitate muscarinic receptor-mediated cytosolic Ca 2ϩ release. As the ability for caveolin-1 to regulate intracellular signaling, including Ca 2ϩ reuptake in smooth muscle cells (29) , has been linked to its unique CSD, we next examined the effects of a synthetic peptide harboring the CSD sequence, linked to the cell-permeable AT protein transduction domain, on ACh-induced [Ca 2ϩ ] i release in human ASM cells (Fig. 8) . Confluent, 3-day serum-deprived human ASM cultures were preincubated with rhodamine-conjugated AT-CSD or amino acid residuematched AT-scrambled-CSD peptide and then loaded with fura-2, and thereafter, changes in [Ca 2ϩ ] i induced by ACh (0.1-1 M) were measured. Phase contrast and fluorescent cell imaging confirmed significant and equal loading of AT-CSD and AT-scrambled-CSD in cells (Fig. 8, A and B) . AT-scrambled-CSD was without effect on baseline and ACh-induced [Ca 2ϩ ] i in all cultures. Although there was no change in baseline [Ca 2ϩ ] i in cells loaded with AT-CSD, the CSD sequence did cause a marked reduction in peak [Ca 2ϩ ] i induced by sub-EC 50 concentrations of ACh (0.1 and 0.01 M; Fig.  8, C and D) . In contrast, we measured no effect of AT-CSD at concentrations of ACh (10 M) above its EC 50 . Notably, ͓N-methyl-3 H͔scopolamine (͓ 3 H͔NMS) dissociation constants (Kd, expressed in nM) and maximal binding sites (Bmax, expressed as fmol/mg protein) were calculated using a total of 8 concentrations of ͓ 3 H͔NMS, each determined in triplicate for each cell line. Three different cell lines were analyzed. Values are represented as means Ϯ SE. m␤CD, methyl-␤-cyclodextrin.
these effects were similar in pattern and magnitude to what we observed for either caveolin-1 siRNA or cholesterol depletion (Figs. 6 and 7) . Together, these observations suggest that caveolin-1, via its CSD, is central to the facilitator role that caveolae play in cytosolic Ca 2ϩ mobilization mediated by muscarinic receptors in human ASM cells.
DISCUSSION
This study identifies caveolin-1 as the principal caveolae marker protein expressed in ASM and demonstrates, for the first time, a direct role for caveolae and caveolin-1 in ASM responses to the physiological agonist ACh. Muscarinic M 3 R and G␣ q/11 are enriched in caveolae-containing membrane microdomains of intact ASM tissue. This association appears to underpin a highly ordered spatial distribution of M 3 R that, like caveolin-1, coalesce into longitudinal linear arrays, which are concomitantly disrupted by cholesterol depletion. Notably, we show that intact caveolae microdomains facilitate ACh and histamine-induced mobilization of cytosolic Ca 2ϩ in cultured contractile canine and human ASM cells and contraction of intact ASM tissue. These results provide the first functional evidence for caveolae in facilitating excitation-contraction coupling in ASM, which is manifest at ACh concentrations equal to or less than its EC 50 value, indicating caveolae modulate sensitivity to ACh but not maximum ASM responses. Moreover, as caveolae depletion did not appear to affect muscarinic receptor availability, an intracellular, postreceptor role for caveolae in ACh-triggered signaling is suggested. Our experiments using siRNA to suppress caveolin-1 protein abundance or using cell-permeable CSD peptide strongly suggest that caveolin-1 orchestrates the role of caveolae in facilitating M 3 R-mediated [Ca 2ϩ ] i release. Collectively, these experiments suggest that, although in the absence of caveolae, receptors, G proteins, second messenger producing enzymes, and ion channels remain more or less operative, caveolae and caveolin-1 fine tune their interactions during excitation-contraction coupling in response to physiologically relevant ACh exposure.
The potential for caveolae to serve as foci for Ca 2ϩ homeostasis in smooth muscle cells is a long-established concept stemming from early observations that caveolae contain high concentrations of Ca 2ϩ (43) . Large conductance Ca 2ϩ -activated K ϩ channels, plasma membrane Ca 2ϩ pump, and TRPC class transient receptor potential channels all localize to caveolae (2, 5, 9, 16 ). An important role in Ca 2ϩ handling is also supported by ultrastructural studies, including those in ASM, that show caveolae are in close proximity to sarcoplasmic reticulum and mitochondria (18, 31) . Kamishima et al. (29) recently reported that caveolae and caveolin-1 modulate the reuptake of Ca 2ϩ by the sarcoplasmic reticulum in isolated arteriolar myocytes after [Ca 2ϩ ] i mobilization is induced. Interestingly, cerebral resistance arterioles from caveolin-1 knockout mice exhibit a marked reduction in the frequency of spontaneous transient outward currents (STOCs; Ref. 11), possibly due to spatial separation of caveolae from the sarcoplasmic reticulum where ryanodine receptor-mediated Ca 2ϩ sparks that trigger STOCs originate (3, 29, 39) . Our electron microscopy analyses confirm that plasma membrane invaginations characteristic of caveolae are depleted from ASM tissue after ␤-CD treatment, supporting the possibility that spatial disruption of Ca 2ϩ nanospaces could contribute to suppressed contractile responses to ACh. Similarly, caveolae depletion caused concomitant disorganization of caveolin-1 and M 3 R in ASM cells, an effect that correlated with reduced mobilization of cytosolic Ca 2ϩ in response to sub-EC 50 concentrations of ACh. It did not appear Cav-1 protein within 24 h, and this was maintained for at least 3 days after transfection in cultures grown in serum-free media. Nonsilencing control siRNA had no effect on Cav-1 protein abundance. Blots were also probed for ␤-actin as a control for equal protein loading. B: 3 days after transfection with control siRNA or Cav-1 siRNA, cells were loaded with fura-2, and after exposure to sub-EC50 concentrations of ACh (0.01 and 0.1 M), changes in [Ca 2ϩ ]i were measured. Cav-1 protein knockdown significantly reduced peak [Ca 2ϩ ]i induced by ACh, whereas control siRNA had no effect. C: in cultures treated with Cav-1 or control siRNA, we also counted the number of cells that were recruited to mount an increase in [Ca 2ϩ ]i in response to 0.01 or 0.1 M ACh. Recruitment frequency was significantly suppressed after Cav-1 knockdown. Data for each condition shown are the means Ϯ SE of 25-45 cells from at least 3 different human ASM cell lines. *P Ͻ 0.05 and ***P Ͻ 0.001 for Cav-1 siRNA vs. nonsilencing control siRNA transfection (unpaired Student's t-test).
that the sarcoplasmic reticulum was compromised as cholesterol depletion was without effect on resting [Ca 2ϩ ] i , and Ca 2ϩ release induced by bradykinin was refractory to caveolae disruption (Fig. 6D) . Interestingly, our experiments using cellpermeable CSD peptide, which competes with binding of caveolin-1 to effector proteins but does not deplete caveolae, revealed a suppression in ACh-induced [Ca 2ϩ ] i that was quantitatively and qualitatively similar to that caused by cholesterol depletion. These findings indicate that, in the absence of spatial separation of caveolae from sarcoplasmic reticulum and mitochondria, caveolin-1 can play a direct role in regulating Ca 2ϩ release triggered by ACh. To clearly discriminate the extent to which the suppression in cytosolic [Ca 2ϩ ] i we observed after caveolae deletion may have been caused by spatial disruption of Ca 2ϩ nanospaces will require future studies using high resolution, real-time assessment of local Ca 2ϩ concentration, inositol trisphosphate (IP 3 ) synthesis, and the distribution of IP 3 receptor, PLC␤, and G␣ q/11 .
In addition to being integral to the spatial organization of Ca 2ϩ nanospaces, caveolae and caveolin-1 may also participation in excitation-contraction coupling by sequestering and regulating effector proteins. The results of our experiments provide important new insight in this area. First, we show that both M 3 R and its associated G protein effector subunit, G␣ q/11 , are sequestered to caveolae microdomains in human and canine ASM. Second, whereas Darby et al. (9) used biochemical fractionation of canine trachealis to show caveolae are enriched in Ca 2ϩ -handling proteins, including L-type Ca 2ϩ channels, calsequestrin, calreticulin, and plasma membrane Ca 2ϩ pump, our experiments are the first to provide a functional link between caveolae and GPCR-induced Ca 2ϩ release in human and canine ASM. Moreover, we show this effect is correlated with a similar suppression in contractile responses. Third, our studies with siRNA confirm that caveolin-1 mediates the facilitator role of caveolae in ACh-induced Ca 2ϩ release, and with cell-permeable peptides we have also established that the NH 2 -terminal CSD is of central importance to this effect. Collectively, these data provide functional confirmation of prior descriptive associations made between caveolae and Ca 2ϩ homeostasis in smooth muscle cells. A key finding of our studies is that caveolae and caveolin-1 appear to be most important in regulating the sensitivity of ASM responses to physiologically relevant concentrations of ACh. A specific role for caveolae under physiologically relevant conditions, in which [Ca 2ϩ ] i rarely exceeds 400 nM, has also been revealed in studies using caveolin blocking antibodies or CSD peptides to investigate Ca 2ϩ reuptake by the sarcoplasmic reticulum in vascular myocytes (29) . In our own experiments, ACh at concentrations below 1 M induced [Ca 2ϩ ] i that was less than 400 nM, and it was only at these points that we observed a suppression in contraction and/or Ca 2ϩ release after cholesterol depletion or treatment with caveolin-1 siRNA or CSD peptide (Fig. 6A) . Conversely, at concentrations of ACh greater than 1 M, which induced maximum increases in [Ca 2ϩ ] i equal to or greater than 600 nM, we observed no effect of caveolae or caveolin-1 interventions. A likely explanation for the differential effects of caveolae disruption on EC 50 and maximum response to ACh is the presence of muscarinic receptor reserve that has been documented in ASM (24, 36) , rendering responses to higher ACh concentrations refractory to any reduction in coupling to G proteins and/or other downstream signaling effectors. As our [H] 3 -NMS-binding assays suggested there was no change in receptor number after caveolae depletion, we tested the functional effects of m␤CD on pilocarpine, a partial muscarinic agonist that requires recruitment of all M 3 R to induce maximum [Ca 2ϩ ] i . Unlike our observations with ACh, both the EC 50 and maximum response induced by pilocarpine were suppressed by caveolae depletion. This supports the conclusion that even though disrupting caveolae inhibits ACh EC 50 , receptor reserve protects against effects on maximum AChinduced responses. These experiments also appear to negate the possibility that divergent m␤CD-sensitive and -insensitive pools of M 3 Rs exist, as might have otherwise been predicted for receptors localized to caveolae-rich or caveolae-deficient membranes, respectively. If caveolae disruption had selective effects on only a portion of receptors, a partial agonist such as pilocarpine would display a biphasic dose-response relationship; at lower concentrations, the agonist would first use fully functional m␤CD-insensitive receptor populations but would then only recruit m␤CD-sensitive receptors when much higher concentrations were added. Figure 6B demonstrates that this is not the case. Collectively, these data suggest that caveolae and caveolin-1 are likely to have significant effects on in vivo responses of smooth muscle encircling the airways. Moreover, this provides solid rationale for future investigation of the role of caveolae and caveolin-1 in ASM function in pathological conditions such as during airway inflammation associated with bronchial asthma.
Receptor-and ligand-specific effects of caveolae and caveolins on smooth muscle contractile responses have been reported. In general, for vascular smooth muscle, caveolae and caveolin appear to facilitate contraction induced by physiological agonists (2, 12, 28, 48) . There are conflicting reports of the effects of caveolae on muscarinic receptor-mediated responses in gastrointestinal smooth muscle; one study showed no change in carbachol-induced responses of tissue from caveolin-1 knockout mice (48) , whereas a recent study showed that ectopic overexpression of caveolin-1 was sufficient to restore muscarinic receptor-mediated contractions in tissue from aged rabbits (50) . Our studies indicate that caveolae and caveolin-1, via its CSD domain, facilitate responses of ASM to low concentration of ACh; however, we also saw that bradykinin-induced mobilization of cytosolic Ca 2ϩ was resistant to caveolae disruption, whereas responses to all concentrations of histamine were suppressed by cholesterol depletion. As the receptors directly involved with mediating Ca 2ϩ mobilization by each of these ligands are coupled to G␣ q/11 , our findings suggest that receptor-specific differences in caveolae regulation may exist. The refractory nature of bradykinin to caveolae depletion markedly contrasts effects on ACh-or histamine-induced Ca 2ϩ release. We have reported that in serum-derived canine ASM cultures, responsiveness to ACh is restricted to elongate, contractile phenotype myocytes, whereas bradykinin responses are restricted to myocytes that do not exhibit the contractile phenotype (37) . As our current study shows that caveolin-1 is abundant and organized into linear arrays only in elongate, contractile myocytes, it is possible that lack of dependency of bradykinin receptors on caveolae in our cultures may relate to their more prominent functional role in noncontractile myocytes. Divergence in effects of caveolae could also be related to dynamic and variable relationships between GPCRs with caveolae, as has been demonstrated in different cells. For example, on ligand binding, ␤ 2 -adrenergic receptors exit caveolae in cardiomyocytes (41) , endothelin ET A receptors remain localized to caveolae in a number of cell lines (35) , and in CHO and HEK cell lines, ectopically expressed B1 and B2 bradykinin receptors translocate into caveolae (47) . Perhaps even more interesting, the same report revealed that although upon binding ligand both bradykinin receptor subtypes can traffic to caveolae and activate PLC␤ via G␣ q/11 , B2 receptors are rapidly internalized and desensitized, whereas B1 receptors remain active and subsequently activate Ras-dependent pathways (47) . Thus there is suggestive evidence that caveolar trafficking of GPCRs, which can be associated with heterologous desensitization, may play a role in defining intracellular signaling responses (14, 38, 41, 47) . In light of the differences we observed for different GPCRs in response to caveolae depletion, future experiments that address this issue in ASM are clearly warranted.
A number of studies suggest a facilitator role for caveolae in GPCR-mediated contraction in vascular smooth muscle (2, 12) and in smooth muscles from the gastrointestinal tract (13), the urogenital tract (32) , and the myometrium (33). Our results showing that caveolae affect the sensitivity of ASM tissue to ACh-induced contraction are consistent with these reports. Although we measured the ability of caveolae and caveolin-1 to facilitate cytosolic Ca 2ϩ mobilization, our studies did not directly assess other mechanisms that could also contribute to the effects of caveolins and caveolae on ASM contraction. For example, caveolin-1 reportedly facilitates the interaction of some GPCRs with G␣ subunits (4) , and it appears to preferentially bind GDP-G␣ q/11 or -G␣ i to its CSD (34, 35) . This suggests that activated, GTP-bound G␣ subunits dissociate from caveolin-1. Although we did observe localization of G␣ q to caveolae microdomains, we did not measure the effects of caveolae depletion or caveolin-1 knockdown on M 3 R-induced G␣ q/11 activation. Also of relevance to GPCR agonists, phosphatidylinositol turnover, which is induced by G␣ q/11 activation of PLC␤ 1 and leads to Ca 2ϩ release from the sarcoplasmic reticulum, is highly compartmentalized to caveolae microdomains (6, 42) . Future studies examining the effects of caveolin-1 and caveolae on ACh-induced IP 3 production in ASM may reveal more precise understanding of the mechanisms regulating Ca 2ϩ release and contraction. Last, the recruitment of activated RhoA and PKC␣, both of which play an important role in Ca 2ϩ -independent contractile responses of smooth muscle, can be blocked by CSD peptides, suggesting an additional pathway to be assessed in future investigations of the role of caveolae in contractile responses of ASM to physiological agonists (51) .
Our observation that muscarinic M 3 R are localized to and functionally dependent on caveolae is of significant importance. Muscarinic M 3 R play an important role in airway physiology and in the pathophysiology of asthma and COPD (22) . Muscarinic M 3 R are the primary muscarinic receptor subtype responsible for contraction of human central and peripheral ASM (45) . In addition, in ASM, M 3 R is the only muscarinic subtype that mediates IP 3 accumulation and is the primary receptor mediating ACh-induced contraction (15, 46) . More recent work also indicates a prominent role for muscarinic M 3 R in regulating airway myocyte proliferation and maturation (19, 20) . Caveolae and caveolins could modulate muscarinic receptor signaling associated with these responses and thus contribute to more chronic aspects of asthma and COPD (21) .
In summary, our results reveal that muscarinic M 3 R and G␣ q/11 are localized to caveolae in ASM. Furthermore, caveolae and caveolin-1 facilitate muscarinic receptor-mediated [Ca 2ϩ ] i signaling and ASM contraction induced by physiologically relevant concentrations of agonist. These effects are mediated by the CSD of caveolin-1, are not associated with alterations in receptor availability, and thus are likely the result of orchestration of key signaling effectors such as G␣ q , second messenger producing enzymes, and ion channels in caveolae. Notably, we observed that caveolae contribute differentially to the facilitation of GPCR signaling in ASM cells, suggesting that unique mechanisms related to specific receptor-ligand interactions are a determinant of the functional significance of caveolae. This indicates that caveolae and caveolin-1 may play a complex role in ASM biology and function in health and disease.
